课题基金 / 基金详情

Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain

Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain
开发 NaV1.7 选择性抑制剂作为疼痛治疗药物
批准号:
8781815
负责人:
George Miljanich
金额:
$68.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-12-15 至 2016-08-31
关键词:
AcuteAdvanced DevelopmentAdverse effectsAffectAffinityAmino AcidsAnalgesicsAnimalsAnosmiaBindingBiological AvailabilityBiological FactorsCardiacCaringCellsChilopodaChinese PeopleCognitionCollectionConfusionCongenital Pain InsensitivityCoupledDataDependenceDevelopmentDisadvantagedDoseDose-LimitingDrowsinessDrug KineticsDrug or chemical Tissue DistributionElectrophysiology (science)EngineeringErythromelalgiaEvaluationExhibitsFamilyFentanylFlushingFundingGenesGeneticHeadHereditary DiseaseHumanHyperactive behaviorIn VitroIndividualInheritedInhibitory Concentration 50Integral Membrane ProteinInvestigationIon ChannelLeadLegal patentLinkLiteratureMeasuresMedicalMetabolicMetabolismModelingMolecular WeightMorphineMutagenesisMutationNauseaNeuraxisNeurologic ExaminationNeuronsOpioidOpioid AnalgesicsOralOxycodonePainPain DisorderPain managementParentsPatientsPatternPeptidesPeripheralPersonal CommunicationPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePharmacological TreatmentPhasePhenotypePositioning AttributePropertyProtein BindingProtein IsoformsProteinsRNA SplicingRattusRelative (related person)Research PersonnelRodentSCN1A proteinSafetySensorySignal TransductionSiteSmall Business Innovation Research GrantSmell PerceptionSodium ChannelSodium Channel BlockersStimulusTherapeuticToxic effectToxinTransgenic MiceVariantVenomsVentilatory Depressionabsorptionaddictionanalogbasechronic paincognitive functioncostdesigndrug candidateexperienceguanidiniumhigh throughput screeninghuman subjectimprovedin vitro Assayin vivoinhibitor/antagonistloss of functionloss of function mutationpatch clamppre-clinicalpreclinical efficacypreclinical safetyprogramspublic health relevancereceptorresearch studyskeletalsmall moleculestemsuccesstransmission processvoltage

项目摘要

项目成果

George Miljanich的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):与阿片类镇痛药相关的副作用,如恶心、嗜睡、呼吸抑制和潜在的成瘾性,正在推动急性、亚急性和慢性疼痛新疗法的设计和开发。电压门控钠离子通道是负责沿导电细胞传递信号的完整膜蛋白。对10个哺乳动物基因进行了测序,它们编码10种不同的通道异构体(NaV1.1-1.9和NaX),每种通道异构体都具有独特的门控特性和细胞和组织分布模式。最近的研究将一种人类Na+通道亚型NaV1.7的遗传功能缺失突变与一种罕见的遗传性疾病先天性疼痛不敏感(CIP)联系起来。CIP患者对正常疼痛刺激的敏感性降低,但感觉或认知功能没有明显缺陷。大量令人信服的证据表明,在正常人群中选择性抑制NaV1.7可以重现CIP的表型。人类NaV蛋白的高度同源性,加上对多个离子通道靶点进行高通量筛选的挑战,阻碍了针对单个NaV亚型开发选择性拮抗剂的大多数努力。最近的研究结果表明,hNaV1.7孔区两个氨基酸的变化是导致天然钠通道拮抗剂家族胍毒素(GTxs)对该亚型的效力降低的原因。这种变异存在于所有已知的hNaV1.7剪接变体中,但未在任何其他人类NaV异构体中发现。在我们的SBIR项目的I期,我们设计并合成了GTx类似物,通过全细胞膜片钳电生理测量,GTx类似物对hNaV1.7的选择性抑制优于其他NaV亚型。在项目的第二阶段,我们的目标是通过集中的中等通量药物化学工作来提高先导化合物的选择性和药物特性,并在临床前安全性和有效性研究中评估最有希望的候选药物作为治疗疼痛的药物。该项目的成功将导致一种或多种高亲和、异构体选择性的NaV1.7抑制剂被提名为疼痛治疗的候选药物。
英文摘要
DESCRIPTION (provided by applicant): Side effects associated with opioid analgesics, such as nausea, drowsiness, respiratory depression, and potential for addiction, are motivating the design and development of new therapies for acute, subacute and chronic pain. Voltage-gated Na+ ion channels are integral membrane proteins responsible for the transmission of signals along electrically conducting cells. Ten mammalian genes have been sequenced, which encode ten distinct channel isoforms (NaV1.1-1.9 and NaX), each having unique gating properties, and cellular and tissue distribution patterns. Recent studies have correlated a hereditary loss-of-function mutation in one human Na+ channel isoform - NaV1.7 - with a rare genetic disorder known as Congenital Insensitivity to Pain (CIP). Individuals with CIP have reduced sensitivity to normally painful stimuli without significant deficits to sensory or cognitive function. A compellin body of evidence indicates that selective inhibition of NaV1.7 in normal humans could recapitulate the phenotype of CIP. The high homology of human NaV proteins, coupled with challenges associated with high-throughput screening against multiple ion channel targets, have thwarted most efforts to develop selective antagonists for individual NaV subtypes. Recent findings indicate that a two amino acid variation in the pore region of hNaV1.7 is responsible for reduced potency of a family of naturally-occurring sodium channel antagonists, the guanidinium toxins (GTxs), against this isoform. This variation is present in all known hNaV1.7 splice variants, but is not found in any other human NaV isoform. In Phase I of our SBIR program, GTx analogues were designed and synthesized that exhibit selective inhibition of hNaV1.7 over other NaV isoforms as measured by whole-cell patch clamp electrophysiology. In Phase 2 of our program, we aim to improve the selectivity and drug properties of our lead compounds with a focused, medium-throughput medicinal chemistry effort, and to evaluate the most promising candidates as therapeutics for pain in preclinical safety and efficacy studies. Success of this program will lead to the nomination of one or more high-affinity, isoform-selective inhibitors of NaV1.7 as drug candidates for pain treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord
  • 批准号:
    8593061
  • 项目类别:
  • 资助金额:
    $28.5万
  • 财政年份:
    2013
  • 负责人:
    George Miljanich
  • 依托单位:
Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel Inhibi
  • 批准号:
    8455846
  • 项目类别:
  • 资助金额:
    $23.62万
  • 财政年份:
    2012
  • 负责人:
    George Miljanich
  • 依托单位:
海外基金